Latest Breaking News On - கெந்நெடீ ப்ரொஃபெஸர் - Page 1 : comparemela.com

Published: Apr 21, 2021 - Backed by leading healthcare investors including SV Health Investors - Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”). The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncolog

United statesUnited kingdomMark colesDavida tuvesonMichael brennerSoumya raychaudhuriJulia wilsonSanofi aventisPhouman ashrafianSusan hillChris buckleyMichaelb brennerDavid tuvesonResearch early developmentSv health investorsKennedy institute of rheumatology